WO2022015069A1 - 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드 - Google Patents
제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드 Download PDFInfo
- Publication number
- WO2022015069A1 WO2022015069A1 PCT/KR2021/009080 KR2021009080W WO2022015069A1 WO 2022015069 A1 WO2022015069 A1 WO 2022015069A1 KR 2021009080 W KR2021009080 W KR 2021009080W WO 2022015069 A1 WO2022015069 A1 WO 2022015069A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- cov
- sars
- present
- acute respiratory
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 101
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 62
- 230000003472 neutralizing effect Effects 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 19
- 229940096437 Protein S Drugs 0.000 claims description 18
- 101710198474 Spike protein Proteins 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 210000000170 cell membrane Anatomy 0.000 claims description 7
- 241000315672 SARS coronavirus Species 0.000 claims description 6
- 102000006240 membrane receptors Human genes 0.000 claims description 5
- 108020004084 membrane receptors Proteins 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 abstract description 7
- 238000001514 detection method Methods 0.000 abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 208000025721 COVID-19 Diseases 0.000 description 17
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 17
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 15
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 12
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 241000700605 Viruses Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 208000001528 Coronaviridae Infections Diseases 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229940123014 DNA polymerase inhibitor Drugs 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical compound C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000019202 Orthocoronavirinae infectious disease Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229940122277 RNA polymerase inhibitor Drugs 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 101001024637 Severe acute respiratory syndrome coronavirus 2 Nucleoprotein Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940113983 lopinavir / ritonavir Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Definitions
- the present invention relates to a peptide having neutralizing activity against severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) of type 2 and uses thereof.
- SARS-Cov-2 severe acute respiratory syndrome coronavirus 2
- Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is a single-stranded RNA (RNA) virus belonging to the subfamily of coronaviruses, and the cause of the outbreak in Wuhan, China in December 2019 The causative virus was first discovered in an unknown pneumonia patient. Not to be confused with Severe Acute Respiratory Syndrome Infectious Disease, the World Health Organization (WHO) also calls it the '2019 coronavirus infection virus' or '2019 coronavirus infectious disease responsible virus'.
- WHO World Health Organization
- antiviral drugs There is no specific treatment yet, but research on antiviral drugs has progressed, and research on antiviral drugs has been conducted, so it is possible to use the RNA polymerase inhibitor remdesivir, the malaria drug chloroquine, and the antiretroviral human immunodeficiency I protease inhibitor lopinavir/ritonavir. It has been reported that antiviral agents exhibit SARS-CoV-2 inhibitory effects at the cellular level. However, therapeutic agents that are known to be effective so far have become a problem because their effectiveness is insignificant or may cause various side effects in actual clinical practice.
- the present inventors have made intensive efforts to develop a new therapeutic agent capable of inhibiting SARS-CoV-2.
- the present invention confirmed that the peptides of the present invention can be usefully used for prevention, improvement or treatment of coronavirus infection. completed.
- One object of the present invention is to provide a peptide that specifically recognizes a protein or a part thereof of type 2 severe acute respiratory syndrome coronavirus (SARS-CoV-2).
- SARS-CoV-2 type 2 severe acute respiratory syndrome coronavirus
- Another object of the present invention is to provide a composition for preventing or treating SARS-CoV-2 infection.
- Another object of the present invention is to provide a method for preventing or treating SARS-CoV-2 infection.
- Another object of the present invention is to provide a composition for use in the prevention or treatment of SARS-CoV-2 infection.
- Another object of the present invention is to provide a composition for detecting SARS-CoV-2.
- Another object of the present invention is to provide a method for detecting SARS-CoV-2.
- Another object of the present invention is to provide a composition for use in the detection of SARS-CoV-2.
- Another object of the present invention is to provide a kit for diagnosing SARS-CoV-2 infection or disease.
- one aspect of the present invention provides a peptide that specifically recognizes a protein of type 2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a part thereof.
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- compositions for preventing or treating SARS-CoV-2 infection comprising the peptide.
- another aspect of the present invention provides a method for preventing or treating SARS-CoV-2 infection, comprising administering the peptide or a composition comprising the peptide to an individual.
- another aspect of the present invention provides the peptide or a composition comprising the peptide for use in the prevention or treatment of SARS-CoV-2 infection.
- composition for detecting SARS-CoV-2 comprising the peptide.
- another aspect of the present invention provides a method for detecting SARS-CoV-2, comprising the step of contacting the peptide or a composition comprising the peptide with a biological sample.
- another aspect of the present invention provides the peptide or a composition comprising the peptide for use in the detection of SARS-CoV-2.
- Another aspect of the present invention provides a kit for diagnosing infection or disease of SARS-CoV-2.
- the peptide comprising an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 6 of the present invention binds to the spike protein on the surface of SARS-CoV-2 to neutralize SARS-CoV-2, thereby causing viruses and host cells Since it has an effect of inhibiting membrane fusion of the SARS-CoV-2 infection, it can be used for prevention, treatment or diagnosis.
- 1 is a graph showing the results of confirming the ability of the peptides of SEQ ID NOs: 1 to 6 of the present invention to bind to the RBD of the SARS-CoV-2 spike protein by ELISA.
- Figure 2 is an ELISA activity of the peptides of SEQ ID NOs: 1 to 6 of the present invention to inhibit the binding of the RBD of the SARS-CoV-2 spike protein to the angiotensin-converting enzyme 2 (ACE2) protein of the host cell. It is a graph showing the confirmed result.
- ACE2 angiotensin-converting enzyme 2
- FIG. 3 shows the results of confirming by Western blot whether the peptides of SEQ ID NOs: 1 to 4 of the present invention have the ability to inhibit the binding of RBD to ACE2 expressed on the cell surface of the human lung cancer cell line A549.
- One aspect of the present invention specifically recognizes a protein or a part thereof of type 2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the sequence of SEQ ID NOs: 1 to 6 It provides a peptide comprising any one amino acid sequence selected from the group consisting of.
- SARS-CoV-2 type 2 severe acute respiratory syndrome coronavirus 2
- the term 'peptide' refers to a linear or cyclic molecule formed by combining amino acid residues with each other by peptide bonds.
- the production of the peptide may be accomplished by a conventional biological or chemical synthesis method known in the art, and for example, it may be achieved by a method such as solid-phase synthesis techniques.
- the 'peptide' may be variants or fragments of amino acids having different sequences by deletion, insertion, substitution, or a combination of amino acid residues within the range that does not affect the function.
- Amino acid exchanges that do not entirely alter the activity of the peptide are known in the art. In some cases, it may be transformed into phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, and the like. Accordingly, the present invention includes peptides having substantially the same amino acid sequence as a peptide comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 6, and variants or active fragments thereof.
- the substantially identical protein is 75% or more, preferably 80% or more, such as 85% or more, 90% or more, 95% or more, 98% or more of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 6 It means an amino acid sequence having % or more, or 99% or more sequence homology, but is not limited thereto.
- the peptide of the present invention may additionally include a targeting sequence, a tag, a labeled residue, an amino acid sequence prepared for a specific purpose to increase the half-life or peptide stability.
- a protecting group may be attached to the -terminus or C-terminus.
- the protecting group may be an acetyl group, a fluorenyl methoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, or polyethylene glycol (PEG). If there is an ingredient, it may be included without limitation.
- the 'stability' is used to include not only stability in vivo , which protects the peptide of the present invention from attack by in vivo protein cleaving enzymes, but also storage stability (eg, storage stability at room temperature).
- the peptide of the invention is selected from the group consisting of:
- WVPYQARVPYPR (SEQ ID NO: 4);
- the peptide of the present invention can specifically bind to the spike protein (S protein) of SARS-CoV-2. More specifically, the peptide of the present invention can specifically bind to a receptor binding domain (RBD) present in the spike protein of SARS-CoV-2.
- S protein spike protein
- RBD receptor binding domain
- the term “specifically binds” means that it binds to a protein of interest, that is, the spike protein of SARS-CoV-2 or RBD, which is a part thereof, but does not substantially recognize and bind other molecules in the sample.
- the peptide of the present invention can inhibit the binding of the spike protein to the cell membrane receptor of the host cell by specifically binding to the spike protein on the surface of SARS-CoV-2.
- the cell membrane receptor of the host cell is angiotensin-converting enzyme 2 (ACE2), and angiotensin-converting enzyme 2 is a transmembrane protein found in eukaryotes and bacteria. It is a receptor used to invade ACE2 (ACE2), and angiotensin-converting enzyme 2 is a transmembrane protein found in eukaryotes and bacteria. It is a receptor used to invade ACE2 (ACE2), and angiotensin-converting enzyme 2 is a transmembrane protein found in eukaryotes and bacteria. It is a receptor used to invade
- the peptide of the present invention can neutralize SARS-CoV-2 by specifically binding to the spike protein RBD on the surface of SARS-CoV-2, and SARS-CoV-2 binds to the cell membrane of the host cell. It was confirmed that it can inhibit
- neutralization refers to the ability to inhibit SARS-CoV-2 replication in vivo and/or in vitro, regardless of the mechanism by which neutralization is achieved.
- the peptide of the present invention neutralizes SARS-CoV-2 by inhibiting SARS-CoV-2 adhesion to a target cell and fusion of the viral membrane with the cell membrane.
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating type 2 severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection comprising the peptide.
- SARS-CoV-2 type 2 severe acute respiratory syndrome coronavirus
- the present invention provides a method for preventing or treating SARS-CoV-2 infection, comprising administering the peptide or a composition comprising the peptide to an individual.
- the present invention also provides the peptide or a composition comprising the peptide for use in the prevention or treatment of SARS-CoV-2 infection.
- the composition is a spike protein on the surface of type 2 severe acute respiratory syndrome coronavirus SARS-CoV-2 infection can be prevented or treated by binding to the host cell and inhibiting the binding of the spike protein to the cell membrane receptor of the host cell.
- the pharmaceutical composition for the prevention or treatment of SARS-CoV-2 infection of the present invention can be prepared according to a conventional method for oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, And it may be formulated and used in the form of a sterile injection solution, and may further include a pharmaceutically acceptable carrier, excipient or diluent in addition to the peptide for formulation.
- the pharmaceutically acceptable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl, which are commonly used in formulation. pyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, and the like.
- the pharmaceutical composition may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components.
- the pharmaceutical composition may be administered orally or parenterally (eg, intramuscularly, intravenously, intraperitoneally, subcutaneously, intradermally, or locally applied) according to a desired method, and the dosage may vary depending on the patient's condition and although it varies depending on body weight, disease severity, drug form, administration route and time, it may be appropriately selected by those skilled in the art.
- parenterally eg, intramuscularly, intravenously, intraperitoneally, subcutaneously, intradermally, or locally applied
- the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
- a 'pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type, severity, and drug activity of the patient; Sensitivity to the drug, administration time, administration route and excretion rate, treatment period, factors including concurrent drugs and other factors well known in the medical field may be determined.
- the pharmaceutical composition may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, may be administered simultaneously with, separately, or sequentially from a conventional therapeutic agent, and may be administered single or multiple. Taking all of the above factors into consideration, it is important to administer an amount capable of obtaining the maximum effect with a minimum amount without side effects, which can be easily determined by those skilled in the art.
- the effective amount of the pharmaceutical composition may vary depending on the patient's age, sex, condition, weight, absorption of the active ingredient into the body, inactivation rate, excretion rate, disease type, and drugs used in combination, the route of administration, the severity of obesity, It may be increased or decreased according to gender, weight, age, etc., for example, the pharmaceutical composition may be administered per 1 kg of the patient's body weight per day, about 0.0001 ⁇ g to 500mg, preferably 0.01 ⁇ g to 100mg.
- the pharmaceutical composition of the present invention may further comprise at least one other therapeutic agent.
- interferon, anti-S protein monoclonal antibody, anti-S protein polyclonal antibody, nucleoside analog, DNA polymerase inhibitor, siRNA agent or therapeutic vaccine as an antiviral drug along with the peptide may include These can be used in combination with the peptides of the present invention.
- “in combination” means following administration as separate formulations or as one single combination formulation simultaneously, or sequentially as separate formulations in any order.
- the 'subject' may be a subject in need thereof that requires administration of the peptide of the present application or a composition comprising the peptide, and the subject in need of the administration is infected with SARS-CoV-2 infection. It may include not only individuals diagnosed with SARS-CoV-2 infection symptoms, but also individuals wishing to administer the disease or symptom to prevent or improve health.
- the 'administration' means providing a predetermined substance to the patient by any suitable method, and the administration route of the peptide of the present invention can be administered orally or parenterally through all general routes as long as it can reach the target tissue. have.
- the peptide or a composition comprising the peptide may be administered by any device capable of transporting an active substance to a target cell.
- the present invention provides a composition for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising the peptide.
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- the present invention also provides a method for detecting SARS-CoV-2, comprising contacting the peptide or a composition comprising the peptide with a biological sample.
- the present invention provides the peptide or a composition comprising the peptide for use in the detection of SARS-CoV-2.
- composition for detecting SARS-CoV-2 of the present invention can be used to detect the presence or absence of SARS-CoV-2 in a biological sample by confirming a reaction after contacting the biological sample with the peptide.
- the peptides of the present invention may be detectably labeled.
- labels that can be used in the present invention include enzymes, radioactive isotopes, colloidal metals, fluorescent compounds, chemiluminescent compounds and bioluminescent compounds.
- Commonly used labels include fluorescent substances (eg, fluorescein, rhodamine, Texas red, etc.), enzymes (eg, horseradish peroxidase, ⁇ -galactosidase, alkaline phosphatase), radioactive isotopes (eg, 32P or 125I), biotin, digoxigenin, colloidal metals, chemiluminescent or bioluminescent compounds (eg, dioxetane, luminol or acridinium). Labeling methods such as covalent bonding of enzymes or biotinyl groups, iodination, phosphorylation, and biotinylation are well known in the art.
- the detection of the presence of SARS-CoV-2 is performed by enzyme immunoassay (ELISA), Western blotting, immunofluorescence, immunohistochemistry staining, flow cytometry, and immune cells.
- enzyme immunoassay ELISA
- Western blotting Western blotting
- immunofluorescence immunofluorescence
- immunohistochemistry staining flow cytometry
- immune cells immune cells.
- any one selected from the group consisting of chemical method, radioimmunoassay (RIA), immunoprecipitation assay, immunodiffusion assay, complement fixation assay, and protein chip can be carried out.
- the enzyme immunosorbent method includes a direct ELISA using a labeled antibody recognizing a peptide attached to a solid support, and an indirect ELISA using a labeled secondary antibody recognizing a capture antibody in a complex of an antibody recognizing a peptide attached to a solid support. It includes various ELISA methods such as ELISA.
- the biological sample may be any one selected from the group consisting of sputum, saliva, blood, sweat, respiratory tissue, and saliva of the subject, but is not limited thereto, and the sample may be prepared by a conventional method known in the art.
- the present invention also provides a kit for diagnosing SARS-CoV-2 infection or disease comprising the peptide.
- SARS-CoV-2 infection or disease refers to a pathological condition resulting from infection of a cell or a subject by SARS-CoV-2, for example, the disease is caused by SARS-CoV-2 It may be caused by respiratory disease.
- the kit may include a solid carrier.
- the peptides of the invention may be attached to a solid carrier, which may be porous or non-porous, planar or non-planar.
- S protein SARS-CoV-2 spike protein
- ACE2 angiotensin-converting enzyme 2
- the 6 types of peptides selected in Experimental Example 1 were mixed with 2 mM sodium bicarbonate in the same volume, dispensed in a 96-well plate at 100 ⁇ L, and then incubated at 4° C. overnight to coat the well surface with the peptide. .
- 100 ⁇ L of 3% BSA was dispensed, blocked at room temperature for 1 hour, and washed 3 times with 0.1% PBS-T. Thereafter, 100 ng of recombinant SARS-CoV-2 spike RBD-His (Sino Biological, Cat.
- the peptide of the present invention has the ability to recognize and bind to the RBD of the SARS-CoV-2 spike protein.
- the peptide of the present invention binds to the RBD of the spike protein of SARS-CoV-2, thereby inhibiting the binding of the spike protein to the ACE2 protein.
- the binding ability of the SARS-CoV-2 spike protein RBD to ACE2 of the host cell after treatment with the peptides in a human lung cancer cell line was confirmed to decrease.
- A549 cells (Korean Cell Line Bank, Cat.No.: 10185, Korea), which are adenocarcinomic human alveolar basal epithelial cells, were inoculated into a 6-well plate at a density of 5x10 5 cells/well and inoculated for 24 hours. cultured. 500 ng of recombinant SARS-CoV-2 spike RBD His (Sino Biological, Cat. No.: 40592-V08B, China) was mixed in 1 mL of DMEM medium and a peptide solution for each concentration was mixed and reacted at room temperature for 1 hour.
- A549 cells cultured for one day were washed with DMEM medium, and then 900 ⁇ L of recombinant SARS-CoV-2 spike RBD/peptide mixture was added to the cells. After culturing for 2 hours in a CO 2 incubator at 37° C., the cells were washed twice with PBS and treated with 200 ⁇ L of lysis buffer to lyse the cells. After preparing a sample by processing 5X sample buffer, SDS-PAGE was performed using a 10% SDS-PAGE gel. Proteins separated by SDS-PAGE were transferred to a PVDF membrane, and then blocked using 5% skim milk at room temperature for 1 hour. Next, anti-His antibody-HRP (Abcam, Cat.
- each of the peptides of SEQ ID NOs: 1 to 4 of the present invention inhibited the binding of ACE2 and SARS-CoV-2 spike RBD in host cells in a concentration-dependent manner.
- the peptide of the present invention binds to the spike protein of SARS-CoV-2 and inhibits the binding of the spike protein to ACE2 of the host cell, thereby preventing or treating virus infection in the host cell. .
- FRNT Focus Reduction Neutralizing Test
- Vero E6 cells ATCC, USA
- Vero E6 cells ATCC, USA
- 500 focus-forming units (FFU)/well of SARS-CoV-2 and peptide samples by concentration were mixed 1:1 and reacted at 37°C for 1 hour.
- the peptide and virus mixture was treated on Vero E6 cell monolayer and incubated at 37 °C for 1 hour.
- DMEM medium containing 1.6% carboxymethylcellulose (CMC) was treated and incubated at 37 °C for 24 hours.
- the cells were fixed by treatment with 4% paraformaldehyde and washed with PBS.
- Cell permeabilization was performed by treatment with PBS containing 0.2% Triton X-100 and 1% BSA for 30 minutes, followed by washing with PBS.
- PBS containing 0.2% Triton X-100 and 1% BSA for 30 minutes, followed by washing with PBS.
- PBST PBS containing 1% Tween
- the peptide of the present invention can prevent, improve and treat SARS-CoV-2 infection by inhibiting cell infection by SARS-CoV-2.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
NO | 서열 | 분자량 (Da) | 서열번호 |
1 | RSYMTTHHEQF | 1437 | 1 |
2 | KFNRRHH | 994.1 | 2 |
3 | KYLLVHRPYYRR | 1664 | 3 |
4 | WVPYQARVPYPR | 1532 | 4 |
5 | RLYCKNGGFFLR | 1474 | 5 |
6 | KHRGGGNRR | 1037 | 6 |
서열번호 | 농도 (mM) | 저해율 (%) |
1 | 2.5 | 21 |
10 | 100 | |
2 | 2.5 | 51 |
10 | 96 | |
3 | 2.5 | 98 |
10 | 98 | |
4 | 2.5 | 55 |
10 | 98 |
Claims (8)
- 제2형 중증급성호흡기증후군 코로나바이러스(Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)의 단백질 또는 그 일부를 특이적으로 인지하고, 서열번호 1 내지 서열번호 6의 서열로 구성된 군에서 선택되는 어느 하나의 아미노산 서열을 포함하는 펩타이드.
- 청구항 1에 있어서,상기 제2형 중증급성호흡기증후군 코로나바이러스의 단백질은 스파이크 단백질인, 펩타이드.
- 청구항 1에 있어서,상기 펩타이드는 제2형 중증급성호흡기증후군 코로나바이러스 표면의 스파이크 단백질에 결합하여 숙주세포의 세포막 수용체와 스파이크 단백질의 결합을 억제하는 것인 펩타이드.
- 청구항 1의 펩타이드를 포함하는 제2형 중증급성호흡기증후군 코로나바이러스(Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) 감염의 예방 또는 치료용 약학적 조성물.
- 청구항 4에 있어서,상기 조성물은 제2형 중증급성호흡기증후군 코로나바이러스 표면의 스파이크 단백질에 결합하여 숙주세포의 세포막 수용체와 스파이크 단백질의 결합을 억제하는 것인, 약학적 조성물.
- 청구항 4에 있어서,상기 약학적 조성물은 약제학적으로 허용되는 담체, 부형제 또는 희석제를 추가로 포함하는 것인, 약학적 조성물.
- 청구항 4에 있어서,상기 약학적 조성물은 경구용 제제, 주사용 제제 또는 외용제의 형태로 제형화되는 것인, 약학적 조성물.
- 청구항 1의 펩타이드를 포함하는 제2형 중증급성호흡기증후군 코로나바이러스(Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) 검출용 조성물.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180060916.4A CN116568699A (zh) | 2020-07-16 | 2021-07-15 | 对严重急性呼吸综合征冠状病毒2具有中和活性的肽 |
BR112023000503A BR112023000503A2 (pt) | 2020-07-16 | 2021-07-15 | Peptídeo com atividade neutralizante contra a síndrome respiratória aguda grave do coronavírus-2 |
JP2023502628A JP7516652B2 (ja) | 2020-07-16 | 2021-07-15 | 重症急性呼吸器症候群コロナウイルス2型に中和活性を有するペプチド |
MX2023000267A MX2023000267A (es) | 2020-07-16 | 2021-07-15 | Peptido con actividad neutralizante contra el coronavirus 2 del sindrome respiratorio agudo grave. |
US18/016,046 US20240051993A1 (en) | 2020-07-16 | 2021-07-15 | Peptide with neutralizing activity against severe acute respiratory syndrome coronavirus 2 |
EP21842944.7A EP4183793A4 (en) | 2020-07-16 | 2021-07-15 | PEPTIDE HAVING NEUTRALIZING ACTIVITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200088076 | 2020-07-16 | ||
KR10-2020-0088076 | 2020-07-16 | ||
KR1020210030604A KR102380735B1 (ko) | 2020-07-16 | 2021-03-09 | 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드 |
KR10-2021-0030604 | 2021-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022015069A1 true WO2022015069A1 (ko) | 2022-01-20 |
Family
ID=79555716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/009080 WO2022015069A1 (ko) | 2020-07-16 | 2021-07-15 | 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20240051993A1 (ko) |
EP (1) | EP4183793A4 (ko) |
JP (1) | JP7516652B2 (ko) |
KR (3) | KR102628158B1 (ko) |
BR (1) | BR112023000503A2 (ko) |
MX (1) | MX2023000267A (ko) |
WO (1) | WO2022015069A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230141227A (ko) * | 2022-03-31 | 2023-10-10 | (주)케어젠 | 항염증 및 항섬유화 활성을 갖는 펩타이드 및 이의 용도 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960015442A (ko) * | 1994-10-20 | 1996-05-22 | 김광호 | 포커스서보제어장치 |
JP2009537143A (ja) * | 2006-05-19 | 2009-10-29 | アムゲン インコーポレイティッド | Sarsコロナウイルスに対する抗体 |
KR20140134083A (ko) * | 2013-05-13 | 2014-11-21 | (주)케어젠 | 비만세포―특이적 아팝토시스-유도용 펩타이드 및 이의 용도 |
KR20170105697A (ko) * | 2016-03-09 | 2017-09-20 | (주)케어젠 | 발모 촉진 활성 및 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 |
KR102081267B1 (ko) * | 2013-05-16 | 2020-02-25 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 헤파란 설페이트 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007009512A (es) | 2005-02-08 | 2008-02-21 | New York Blood Ct Inc | Neutralizacion de anticuerpos monoclonales contra coronavirus asociado con sindrome respiratorio agudo severo. |
KR101381337B1 (ko) * | 2005-07-26 | 2014-04-11 | 씨엠에스 펩티드 패턴트 홀딩 컴퍼니 리미티드 | 신규한 생물학적 활성 펩티드 및 그의 신규한 용도 |
US20070160981A1 (en) * | 2005-10-24 | 2007-07-12 | Xin Chen | Viral protease |
KR20080012449A (ko) * | 2006-08-03 | 2008-02-12 | 재단법인서울대학교산학협력재단 | 뉴클레오캡시드 또는 스파이크 단백질을 이용한 사스진단방법 |
EP2360173B1 (en) | 2008-11-28 | 2016-01-13 | NOF Corporation | Cytotoxic t cell epitope peptide for sars coronavirus, and use thereof |
KR101895228B1 (ko) * | 2017-08-23 | 2018-10-30 | 대한민국 | 중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도 |
KR101916899B1 (ko) * | 2017-08-31 | 2018-11-08 | 한국생명공학연구원 | Sars 관련 코로나바이러스 및 mers 관련 코로나바이러스 동시 검출용 프라이머 및 이를 이용한 검출 방법 |
KR102019008B1 (ko) | 2019-01-31 | 2019-09-05 | 대한민국(관리부서 질병관리본부장) | 메르스 코로나바이러스 뉴클레오캡시드 융합 단백질을 이용한 메르스 코로나바이러스 검출 방법 |
-
2021
- 2021-07-15 US US18/016,046 patent/US20240051993A1/en active Pending
- 2021-07-15 BR BR112023000503A patent/BR112023000503A2/pt unknown
- 2021-07-15 JP JP2023502628A patent/JP7516652B2/ja active Active
- 2021-07-15 EP EP21842944.7A patent/EP4183793A4/en active Pending
- 2021-07-15 MX MX2023000267A patent/MX2023000267A/es unknown
- 2021-07-15 WO PCT/KR2021/009080 patent/WO2022015069A1/ko active Application Filing
- 2021-08-20 KR KR1020210109990A patent/KR102628158B1/ko active IP Right Grant
- 2021-08-20 KR KR1020210109989A patent/KR102621336B1/ko active IP Right Grant
- 2021-08-20 KR KR1020210109991A patent/KR102628159B1/ko active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960015442A (ko) * | 1994-10-20 | 1996-05-22 | 김광호 | 포커스서보제어장치 |
JP2009537143A (ja) * | 2006-05-19 | 2009-10-29 | アムゲン インコーポレイティッド | Sarsコロナウイルスに対する抗体 |
KR20140134083A (ko) * | 2013-05-13 | 2014-11-21 | (주)케어젠 | 비만세포―특이적 아팝토시스-유도용 펩타이드 및 이의 용도 |
KR102081267B1 (ko) * | 2013-05-16 | 2020-02-25 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 헤파란 설페이트 |
KR20170105697A (ko) * | 2016-03-09 | 2017-09-20 | (주)케어젠 | 발모 촉진 활성 및 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 |
Non-Patent Citations (1)
Title |
---|
See also references of EP4183793A4 * |
Also Published As
Publication number | Publication date |
---|---|
US20240051993A1 (en) | 2024-02-15 |
KR20220009926A (ko) | 2022-01-25 |
MX2023000267A (es) | 2023-02-13 |
EP4183793A1 (en) | 2023-05-24 |
KR102621336B1 (ko) | 2024-01-08 |
BR112023000503A2 (pt) | 2023-01-31 |
JP7516652B2 (ja) | 2024-07-16 |
KR102628159B1 (ko) | 2024-01-24 |
JP2023534947A (ja) | 2023-08-15 |
KR102628158B1 (ko) | 2024-01-24 |
KR20220009925A (ko) | 2022-01-25 |
EP4183793A4 (en) | 2024-05-22 |
KR20220009924A (ko) | 2022-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cinatl Jr et al. | Development of antiviral therapy for severe acute respiratory syndrome | |
US20100112547A1 (en) | Methods and compositions for diagnosis and treatment of influenza | |
WO2022015069A1 (ko) | 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드 | |
Khan et al. | Diagnostic approaches and potential therapeutic options for coronavirus disease 2019 | |
TW202202167A (zh) | 醫藥用途 | |
EP1719515A2 (en) | Glycyrrhizin or derivatives thereof for treating or preventing togavirus infections | |
Kooshkaki et al. | Coronavirus disease 2019: a brief review of the clinical manifestations and pathogenesis to the novel management approaches and treatments | |
KR102380735B1 (ko) | 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드 | |
Kaur et al. | COVID-19 infection: epidemiology, virology, clinical features, diagnosis and pharmacological treatment | |
Zahn et al. | Persistence of infectious SARS‐CoV‐2 particles for up to 37 days in patients with mild COVID‐19 | |
WO2019208995A1 (ko) | 신규한 중증열성혈소판감소증후군 바이러스 | |
JP7302795B2 (ja) | コロナウイルスの感染防御方法 | |
Borges-Velez et al. | SARS-CoV-2: Biology, detection, macrophage mediated pathogenesis and potential treatments | |
CN116568699A (zh) | 对严重急性呼吸综合征冠状病毒2具有中和活性的肽 | |
EP1901071B1 (en) | Methods for screening an anti-hepatitis c virus candidate | |
WO2023063738A1 (ko) | 항-ace2 항체가 부착된 중간엽 줄기세포 유래 세포외소포체 및 이의 용도 | |
US6287605B1 (en) | Compositions and methods useful in treatment and prevention of HIV-1 infection | |
WO2022154267A2 (ko) | ACE2에 결합하는 SARS-CoV2에 대한 항 바이러스 항체 및 이의 용도 | |
US20230181681A1 (en) | Peptide for suppressing coronavirus and use thereof | |
TW202223393A (zh) | 診斷及治療嚴重特殊傳染性肺炎covid-19的組成物及方法 | |
WO2022177341A1 (ko) | 항암제에 대한 내성 진단용 조성물 | |
US20230390235A1 (en) | Therapeutic agent for covid-19 | |
Moharana et al. | Evolution of experimental techniques & control measures in COVID-19 reservoir studies: A systematic review | |
Pérez et al. | Evaluation of immune response, comorbidities and immunomodulation in SARS-CoV2 pandemic | |
THAKUR et al. | Possible potential treatment strategies against novel coronavirus SARS-CoV-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21842944 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202217075793 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2023502628 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180060916.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 140150140003007577 Country of ref document: IR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023000503 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112023000503 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230111 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021842944 Country of ref document: EP Effective date: 20230216 |